<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Metx — News on 6ix</title>
<link>https://6ix.com/company/metx</link>
<description>Latest news and press releases for Metx on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/metx" rel="self" type="application/rss+xml" />
<item>
<title>ME Therapeutics Provides Scientific Update on In Vivo CAR and Therapeutic mRNA Programs</title>
<link>https://6ix.com/company/metx/news/me-therapeutics-provides-scientific-update-on-in-vivo-car-and-therapeutic-mrna-programs</link>
<guid isPermaLink="true">https://6ix.com/company/metx/news/me-therapeutics-provides-scientific-update-on-in-vivo-car-and-therapeutic-mrna-programs</guid>
<pubDate>Wed, 29 Apr 2026 13:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, April 29, 2026--ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide an update on recent advances within its in vivo CAR and therapeutic mRNA research and development programs.</description>
</item>
<item>
<title>ME Therapeutics Scientific and Corporate Update</title>
<link>https://6ix.com/company/metx/news/therapeutics-scientific-corporate-140000864</link>
<guid isPermaLink="true">https://6ix.com/company/metx/news/therapeutics-scientific-corporate-140000864</guid>
<pubDate>Fri, 30 Jan 2026 14:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, January 30, 2026--ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide a corporate update and an outline of its strategic positioning within the rapidly emerging in vivo immune cell engineering and chimeric antigen receptor (CAR) space.</description>
</item>
<item>
<title>ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program</title>
<link>https://6ix.com/company/metx/news/therapeutics-granted-licence-cd22-nanobody-130000586</link>
<guid isPermaLink="true">https://6ix.com/company/metx/news/therapeutics-granted-licence-cd22-nanobody-130000586</guid>
<pubDate>Thu, 16 Oct 2025 13:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, October 16, 2025--ME Therapeutics has entered into a technology license agreement with the National Research Council of Canada to license a nanobody-based CD22 binder.</description>
</item>
<item>
<title>ME Therapeutics Added to CSE25 Index</title>
<link>https://6ix.com/company/metx/news/therapeutics-added-cse25-index-130000426</link>
<guid isPermaLink="true">https://6ix.com/company/metx/news/therapeutics-added-cse25-index-130000426</guid>
<pubDate>Fri, 10 Oct 2025 13:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, October 10, 2025--ME Therapeutics Holdings Inc. announced today it has been added to the CSE25 Index, a signature benchmark of the Canadian Securities Exchange.</description>
</item>
<item>
<title>ME Therapeutics Secures U.S. Patent for Lead Candidate and Advances Broader Therapeutic Programs</title>
<link>https://6ix.com/company/metx/news/therapeutics-secures-u-patent-lead-130000462</link>
<guid isPermaLink="true">https://6ix.com/company/metx/news/therapeutics-secures-u-patent-lead-130000462</guid>
<pubDate>Fri, 26 Sep 2025 13:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, September 26, 2025--ME Therapeutics secures U.S. patent for lead candidate and advances broader therapeutic programs.</description>
</item>
<item>
<title>ME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory Disease</title>
<link>https://6ix.com/company/metx/news/therapeutics-receives-support-advance-mrna-100000369</link>
<guid isPermaLink="true">https://6ix.com/company/metx/news/therapeutics-receives-support-advance-mrna-100000369</guid>
<pubDate>Wed, 21 May 2025 10:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, May 21, 2025--ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed preclinical biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, today announced that its subsidiary, ME Therapeutics Inc., is receiving advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The project will support t</description>
</item>
<item>
<title>ME Therapeutics Announces It Has Engaged Lucosky Brookman LLP to Explore a Listing on the NASDAQ or NYSE</title>
<link>https://6ix.com/company/metx/news/therapeutics-announces-engaged-lucosky-brookman-140000248</link>
<guid isPermaLink="true">https://6ix.com/company/metx/news/therapeutics-announces-engaged-lucosky-brookman-140000248</guid>
<pubDate>Mon, 03 Mar 2025 14:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - March 3, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announced that it has retained Lucosky Brookman LLP, a distinguished corporate finance and securities law firm, to assist in evaluating an uplisting to a senior national securities exchange such as the Nasdaq Capital</description>
</item>
</channel>
</rss>